This page shows the publications co-authored by Frank Hodi and Howard Kaufman.
An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0. J Immunother Cancer. 2018 05 30; 6(1):44.
Cancer immunotherapy trials: leading a paradigm shift in drug development. J Immunother Cancer. 2016; 4:42.
Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy. Expert Rev Anticancer Ther. 2015; 15(12):1389-403.
The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol. 2013 10; 10(10):588-98.
Combination immunotherapy: a road map. J Immunother Cancer. 2017; 5:16.
Defining the critical hurdles in cancer immunotherapy. J Transl Med. 2011 Dec 14; 9:214.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.